Extending the stroke treatment window beyond DAWN in patients with very slow progressor type collaterals: How far can we go?
10.7461/jcen.2021.E2021.01.003
- Author:
Igor PAGIOLA
1
;
Olivier CHASSIN
;
Sophie GALLAS
;
Mariana Sarov RIVIERE
;
Nicolas LEGRIS
;
Cristian MIHALEA
;
Jildaz CAROFF
;
Leon IKKA
;
Vanessa CHALUMEAU
;
Guilherme Brasileiro de AGUIAR
;
Augustin OZANNE
;
Jacques MORET
;
Christian DENIER
;
Laurent SPELLE
Author Information
1. Department of Interventional Neuroradiology Neuri Brain Vascular Center, Hopital Bicetre, APHP, Paris Sud Université, France
- Publication Type:Case Report
- From:Journal of Cerebrovascular and Endovascular Neurosurgery
2021;23(4):354-358
- CountryRepublic of Korea
- Language:English
-
Abstract:
Five trials published in 2015 showed the benefit of endovascular thrombectomy (ET) in patients with stroke and large vessel occlusion, extending the treatment window has become an obsession of all physicians. In 2018, the DAWN and DEFUSE-3 trials showed that, with careful selection of patients, the procedure could be carried out up to 24 hours after symptom onset with good outcomes. In addition, there have been cases where the DAWN criteria were met, and treatment occurred >24 hours after symptom onset. We present the case of a 68-year-old female whose groin puncture occurred 52 hours after the time last known well (TLKW), after neurological worsening of the initial situation, with a large mismatch ratio observed on magnetic resonance imaging, achieving TICI (the Thrombolysis in Cerebral Infarction scale) grade 3 recanalization. Five days after the procedure, the patient was discharged with NIHSS (National Institutes of Health Stroke Scale) score of 3. Some types of collateral circulation (slow progressors and “turtle” progressors, our term for very slow progressors) can extend the treatment window beyond 24 hours of the TLKW but can lead to a hyperperfusion-like syndrome immediately after the ET. Further studies are needed to evaluate the reproducibility of this hypothetical syndrome.